Company Fennec Pharmaceuticals Inc. Nasdaq
Equities
CA31447P1009
Biotechnology & Medical Research
Business Summary
Number of employees: 29
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sodium Thiosulfate
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07/09/07 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 25/14/25 |
Mark Gowland
AUD | Comptroller/Controller/Auditor | 52 | 01/15/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25/11/25 |
Khalid Islam
CHM | Chairman | 67 | 25/14/25 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 25/14/25 |
Marco Brughera
BRD | Director/Board Member | 70 | 10/16/10 |
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07/09/07 |
Jodi Cook
BRD | Director/Board Member | 56 | 24/19/24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,322,141 | 22,174,779 ( 81.16 %) | 0 | 81.16 % |
Company contact information
Fennec Pharmaceuticals, Inc.
Research Triangle Park 68 T.W. Alexander Drive
27709, Durham
+919 636 4530
http://www.fennecpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |